Botulinum Neurotoxin Trafficking and Tissue Distribution with Mouse Body Imaging

Information

  • Research Project
  • 8828345
  • ApplicationId
    8828345
  • Core Project Number
    R03AI103868
  • Full Project Number
    7R03AI103868-02
  • Serial Number
    103868
  • FOA Number
    PA-14-078
  • Sub Project Id
  • Project Start Date
    5/23/2013 - 12 years ago
  • Project End Date
    4/30/2016 - 9 years ago
  • Program Officer Name
    RANALLO, RYAN
  • Budget Start Date
    5/1/2014 - 11 years ago
  • Budget End Date
    4/30/2016 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/13/2014 - 10 years ago
Organizations

Botulinum Neurotoxin Trafficking and Tissue Distribution with Mouse Body Imaging

DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs), classified as category A bioterrorism agent(s) by the Centers for Disease Control (CDC), are the most toxic substances known to mankind. At the same time BoNTs are also used as effective therapeutics against numerous neuro-muscular disorders as well as for aesthetic puproses. In its native form, BoNTs are secreted in complex forms, consisting of the 150 kDa neurotoxin and a group of neurotoxin-associated proteins (NAPs) which protect the toxin against low pH and proteases in the GI tract. Virtually all the current therapeutic products are in the complex form. Recent growth in the use of BoNTs for clinical applications, and its black box label designation by FDA, warrants a more in depth understanding of the toxin's movement from the site of its administration to various tissues and organs. Moreover, real-time uptake and trafficking information is essential to devise adequate interventions in case of food poisoning and intentional exposure cases of bioterrorism or a WMD attack in war theater. We propose to establish disposition of BoNT's within the body of a mouse model, after administering it through various routes of entry using bio-imaging technology and a non-toxic surrogate of type A BoNT (BoNT/A). We plan to address several critical questions relevant to dose, route, and rate of trafficking; and will also examine utility of the system for assessing the distribution of the toxi in different tissues. At the end of this proposed pilot study, we expect to have established a surrogate molecule (drBoNT/A) for visualization of BoNT/A uptake, trafficking, tissue distribution, and elimination routes after administration by different routes (oral, ip, intranasal etc.). The information derived from operation of such a system will be relevant to medical intervention against botulism, potential diffusion of the toxin upon therapeutic application, and t effective use of the drBoNT/A as a potential drug delivery vehicle to nerves in different tissues.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R03
  • Administering IC
    AI
  • Application Type
    7
  • Direct Cost Amount
    50000
  • Indirect Cost Amount
    20000
  • Total Cost
    70000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:70000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    CMIP
  • Study Section Name
    Clinical Molecular Imaging and Probe Development
  • Organization Name
    PRIME BIO, INC.
  • Organization Department
  • Organization DUNS
    030446897
  • Organization City
    NORTH DARTMOUTH
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    027471008
  • Organization District
    UNITED STATES